100% Active SAM-e (S,S-Isomerpurity)

by Posted on

Substantiation That the Structure/Function Claims (SFCs) Are Truthful and Not Misleading

Product Information:

  • Brand Name: Nugenis
  • Dietary Supplement Name: 100% Active SAM-e (S,S-Isomerpurity)
  • Dietary Ingredient: S-Adenosyl-L-Methionine (SAM-e) (S,S-Isomer)

Claim 1: Supports Emotional Well-Being

Ingredient: S-Adenosyl-L-Methionine (SAM-e)

Mechanism of Action:

  • SAM-e serves as a methyl donor in neurotransmitter metabolism, particularly for serotonin, dopamine, and norepinephrine.
  • It facilitates methylation reactions essential for mood regulation by enhancing phosphatidylcholine synthesis, improving neuronal membrane fluidity.

Supporting Scientific Evidence:

  • Multiple randomized controlled trials (RCTs) and meta-analyses support SAM-e’s efficacy in mood enhancement comparable to standard antidepressants (e.g., SSRIs).
  • A meta-analysis (Papakostas et al., 2010) concluded that SAM-e significantly improves depressive symptoms with fewer side effects than traditional antidepressants.
  • Dosages between 200–1600 mg daily align with effective levels used in clinical studies.

Claim 2: Supports Joint Health

Ingredient: S-Adenosyl-L-Methionine (SAM-e)

Mechanism of Action:

  • SAM-e plays a role in cartilage maintenance by increasing proteoglycan synthesis in chondrocytes.
  • Acts as an anti-inflammatory agent, reducing cytokine levels (e.g., TNF-alpha, IL-6) associated with joint degradation.

Supporting Scientific Evidence:

  • A meta-analysis (Soeken et al., 2002) reviewed SAM-e’s effectiveness in osteoarthritis and found comparable efficacy to NSAIDs in pain reduction and functional improvement.
  • Studies indicate that 600–1200 mg daily improves joint mobility and reduces pain over 8–12 weeks.

Claim 3: Supports Liver Function

Ingredient: S-Adenosyl-L-Methionine (SAM-e)

Mechanism of Action:

  • SAM-e enhances glutathione synthesis, a crucial antioxidant for liver detoxification.
  • It promotes membrane integrity in hepatocytes, protecting against oxidative stress and liver fibrosis.

Supporting Scientific Evidence:

  • Clinical studies (Mato et al., 1999) demonstrate improvements in hepatic function in cholestatic liver diseases.
  • A review by Anstee et al. (2015) supports SAM-e’s hepatoprotective effects in conditions like NAFLD and liver cirrhosis at doses of 800–1600 mg daily.

Claim 4: 100% Active SAM-e (S,S-Isomer) – Exclusion of R,S-Isomer

Significance of the S,S-Isomer:

  • The S,S-isomer is the biologically active form that participates in methylation reactions, whereas the R,S-isomer is inactive and may reduce efficacy.
  • The exclusion of the R,S-isomer enhances bioavailability, ensuring maximal absorption and therapeutic effect.

Supporting Scientific Evidence:

  • Studies (Bottiglieri, 2002) confirm that only the S,S-isomer integrates effectively into cellular metabolism.
  • Higher isomeric purity correlates with greater bioefficacy in SAM-e supplementation.

Analytical Verification & Quality Control:

  • High-performance liquid chromatography (HPLC) and chiral separation confirm isomeric purity.
  • Manufacturing processes rigorously eliminate the R,S-isomer to maintain a 100% active formulation.

Contraindications & Precautions:

  • SAM-e is not recommended for individuals with bipolar disorder due to potential manic episodes.
  • Should not be combined with antidepressants (SSRIs, MAOIs) without medical supervision.
  • Consultation with a physician is advised for pregnant/nursing individuals and those with existing medical conditions.

References & Literature Cited:

  1. Papakostas, G. I., et al. (2010). „S-Adenosyl-L-Methionine (SAMe) for Major Depressive Disorder: A Meta-Analysis.“ American Journal of Psychiatry.
  2. Soeken, K. L., et al. (2002). „SAMe as Treatment for Osteoarthritis: A Meta-Analysis.“ Journal of Family Practice.
  3. Mato, J. M., et al. (1999). „S-Adenosylmethionine in Liver Health and Disease.“ Hepatology.
  4. Bottiglieri, T. (2002). „S-Adenosylmethionine and its Influence on Neurotransmitters and Methylation in the CNS.“ American Journal of Clinical Nutrition.

Conclusion:

  • Claims are substantiated with clinical trials, meta-analyses, and peer-reviewed research.
  • Dosages in Nugenis SAM-e align with evidence-based therapeutic ranges.
  • Analytical verification ensures high purity and efficacy of the S,S-isomer.
  • Product labeling is truthful, not misleading, and meets FDA guidelines under Section 403(r)(6).

© 2025 Eduard Rappold – NUGENIS. Alle Rechte vorbehalten.

Dr. Eduard Rappold, MSc ist ein erfahrener Forscher und Arzt, der sich seit Jahrzehnten für geriatrische PatientInnen einsetzt. In seinem Bemühen für Alzheimer-Erkrankte eine immer bessere Versorgung zu ermöglichen, wurde er 2003 mit dem Gesundheitspreis der Stadt Wien für das Ernährungszustandsmonitoring von Alzheimer-Kranken ausgezeichnet. Im Zuge seines Masterstudiums der Geriatrie hat er seine Entwicklung des Epigenetic Brain Protector wissenschaftlich fundiert und empirisch überprüft. Im September 2015 gründete er NUGENIS, ein Unternehmen, mit dem er Wissenschaft und Anwendung zusammenbringen möchte. Damit können Menschen unmittelbar von den Ergebnissen der Angewandten Epigenetik für ihre Gesundheit profitieren. Mit dem Epigenetic Brain Protector hat Dr. Eduard Rappold, MSc bereits für internationales Aufsehen gesorgt – auf der international wichtigsten Innovationsmesse, der iENA, wurde er 2015 mit einer Goldmedaille für hervorragende Leistungen zum Schutz vor Neurodegeneration ausgezeichnet. Auf den Webseiten nugenis.eu, epigenetik.at, spermidine-soyup.com und facebook.com/nugenis können Themen zur Epigenetik und Aktuelles nachgelesen werden.